Imugene (ASX:IMU) Presents New PD1-Vaxx Data at 2022 WCLC

Be the First to Comment Read
Sponsored

Imugene (ASX:IMU) Presents New PD1-Vaxx Data at 2022 WCLC

 Imugene (ASX:IMU) Presents New PD1-Vaxx Data at 2022 WCLC
Image source: © Mast3r | Megapixl.com

 

Highlights

  • Imugene Limited (ASX:IMU) has presented new data from non-small cell lung cancer patients in the Phase I IMPRINTER study at the IASLC 2022 World Conference on Lung Cancer.
  • The IMPRINTER trial is an ongoing open-label dose escalation study of IMU-201 (PD1-Vaxx) as a monotherapy (Phase 1) or in combination with atezolizumab (Phase 1b).
  • As per the Phase 1 exploratory biomarker data of IMU-201 antibody production, IMU-201 is immunogenic and causes a sustained, antibody response.

One of the leading clinical-stage immuno-oncology companies, Imugene Limited (ASX:IMU), showcases new data from non-small cell lung cancer patients in the Phase I IMPRINTER study at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022). The event, scheduled from 6-9 August in Vienna, is being conducted in-person as well as online.

The poster presentation was titled “Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer”. It was presented by Professor Michael Boyer M.D., MBBS, FRACP, PhD, Chris O’Brien Lifehouse Hospital.

An overview of IMPRINTER trial

The IMPRINTER trial is an ongoing open-label dose escalation study of IMU-201 as a monotherapy (Phase 1) or in combination with atezolizumab (Phase 1b) for non-small cell lung cancer (NSCLC) patients expressing PD-L1.

All subjects recruited in the Phase I IMPRINTER study must have previously received an immune checkpoint inhibitor (ICI) and experienced disease progression. In Phase 1b, recruited patients are either ICI-naïve or have previously received an ICI-containing regimen and progressed on or after this treatment.

Primarily, the trial aims to evaluate the tolerability and safety of IMU-201 as a monotherapy or in combination with atezolizumab and identify the optimal biological dose (OBD). Its secondary objective includes the evaluation of the efficacy of IMU-201 as a monotherapy or in combination with atezolizumab. Also, the study is being conducted with the exploratory objective to evaluate humoral and cellular immunogenicity data. This data would include details about vaccine-specific cytokine levels, IMU-201 and PD-1 specific antibodies (IgG, IgM) and regulatory and effector T and B cells.

Image Source: Company Announcement

Phase 1 exploratory biomarker of IMU-201 antibody production

Image© 2022 Kalkine Media®

As per exploratory biomarker data, IMU-201 is immunogenic and causes a sustained, antibody response. By the sixth week, antibodies to IMU-201 were generated and sustained at high titers during treatment with 100 μg PD1-Vaxx. A dose-dependent increase in antibody production in patients receiving the 100 μg dose was noted.

 
Image Source: Company Announcement

Using this data, the evaluation of IMU-201 in NSCLC can be taken forward. In the next step, the immune-mediated response to IMU-201 will be evaluated and combined with checkpoint inhibitor, atezolizumab.


Image Source: ©2022 Kalkine Media®

Imugene’s shares are trading at AU$0.282 as of 11:42 AM AEST.

 

Disclaimer

Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK